A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/22 (2006.01) A61K 9/20 (2006.01) A61K 47/30 (2006.01)
Patent
CA 2312710
Depot drug formulations include the pharmaceutical itself and a three component release rate controlling matrix composition. The three components of the matrix composition are (1) a pH dependent gelling polymer such as an alginate component; (2) an enteric polymer component, such as Eudragit® L or S; and (3) a pH independent gelling polymer, such as hydroxy propyl methyl cellulose or polyethylene oxide. The drug release rate can be adjusted by changing the amount of one or more of these components of the composition.
Formulations de médicaments destinées à des implants et comprenant l'agent pharmaceutique lui-même et une composition matrice servant à contrôler la vitesse de libération du médicament et constituée par trois éléments. Ces derniers consistent (1) en un polymère de gélification dépendant du pH, tel qu'un constituant d'alginate, (2) en un élément polymère gastro-résistant, tel qu'Eudragit3 L ou S et (3) en un polymère de gélification indépendant du pH, tel que hydroxypropylméthylcellulose ou oxyde de polyéthylène. On peut régler la vitesse de libération du médicament par modification de la quantité d'un ou de plusieurs des constituants de la composition.
Ali Muhammad
Pinnamaraju Prasad
Zhang Guohua
Duramed Pharmaceuticals Inc.
Sim & Mcburney
Teva Women's Health Inc.
LandOfFree
Sustained release formulation containing three different... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release formulation containing three different..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release formulation containing three different... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1374225